{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T21:33:02Z","timestamp":1793309582507,"version":"4.5.0"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004433","name":"Chinese Pharmaceutical Association","doi-asserted-by":"publisher","award":["CPAZ05-ZC-2022-002"],"award-info":[{"award-number":["CPAZ05-ZC-2022-002"]}],"id":[{"id":"10.13039\/501100004433","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100016359","name":"Zhongnan Hospital of Wuhan University","doi-asserted-by":"publisher","award":["ZNQNJC2023010"],"award-info":[{"award-number":["ZNQNJC2023010"]}],"id":[{"id":"10.13039\/501100016359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016966","name":"Bethune Charitable Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016966","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"published-print":{"date-parts":[[2027,1]]},"DOI":"10.1016\/j.jpba.2026.117752","type":"journal-article","created":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T15:25:17Z","timestamp":1790954717000},"page":"117752","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["LC-MS\/MS method for quantification of dupilumab in human serum using Protein G enrichment"],"prefix":"10.1016","volume":"283","author":[{"given":"Kun","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianhua","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengming","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpba.2026.117752_bib1","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/cea.13491","article-title":"Mechanisms of dupilumab","volume":"50","author":"Harb","year":"2020","journal-title":"Clin. Exp. Allergy"},{"key":"10.1016\/j.jpba.2026.117752_bib2","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1111\/all.14151","article-title":"Dual blockade of IL-4 and IL-13 with dupilumab, an IL-4R\u03b1 antibody, is required to broadly inhibit type 2 inflammation","volume":"75","author":"Le Floc'h","year":"2020","journal-title":"Allergy"},{"key":"10.1016\/j.jpba.2026.117752_bib3","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.alit.2020.01.002","article-title":"Dupilumab: basic aspects and applications to allergic diseases","volume":"69","author":"Matsunaga","year":"2020","journal-title":"Allergol. Int."},{"key":"10.1016\/j.jpba.2026.117752_bib4","doi-asserted-by":"crossref","DOI":"10.1111\/cts.13899","article-title":"Dupilumab: mechanism of action, clinical, and translational science","volume":"17","author":"McCann","year":"2024","journal-title":"Clin. Transl. Sci."},{"key":"10.1016\/j.jpba.2026.117752_bib5","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.2217\/imt-2020-0175","article-title":"Dupilumab use in atopic dermatitis and beyond in skin diseases","volume":"12","author":"Fourzali","year":"2020","journal-title":"Immunotherapy"},{"key":"10.1016\/j.jpba.2026.117752_bib6","doi-asserted-by":"crossref","first-page":"3398","DOI":"10.1111\/all.15439","article-title":"Patient-centered dupilumab dosing regimen leads to successful dose reduction in persistently controlled atopic dermatitis","volume":"77","author":"Spekhorst","year":"2022","journal-title":"Allergy"},{"key":"10.1016\/j.jpba.2026.117752_bib7","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1016\/j.jid.2023.03.1659","article-title":"Biological tipping point in patients with atopic dermatitis treated with different dosing intervals of dupilumab","volume":"143","author":"Dekkers","year":"2023","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.jpba.2026.117752_bib8","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1186\/1743-422X-8-419","article-title":"An overview on ELISA techniques for FMD","volume":"8","author":"Ma","year":"2011","journal-title":"Virol. J."},{"key":"10.1016\/j.jpba.2026.117752_bib9","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1208\/s12248-011-9251-3","article-title":"Bioanalytical approaches to quantify \"total\" and \"free\" therapeutic antibodies and their targets: technical challenges and PK\/PD applications over the course of drug development","volume":"13","author":"Lee","year":"2011","journal-title":"AAPS J."},{"key":"10.1016\/j.jpba.2026.117752_bib10","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1093\/clinchem\/hvaa179","article-title":"Development of label-free immunoassays as novel solutions for the measurement of monoclonal antibody drugs and antidrug antibodies","volume":"66","author":"Luo","year":"2020","journal-title":"Clin. Chem."},{"key":"10.1016\/j.jpba.2026.117752_bib11","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1097\/FTD.0000000000000419","article-title":"Immunoassays for measuring serum concentrations of monoclonal antibodies and anti-biopharmaceutical antibodies in patients","volume":"39","author":"Darrouzain","year":"2017","journal-title":"Ther. Drug. Monit."},{"key":"10.1016\/j.jpba.2026.117752_bib12","doi-asserted-by":"crossref","first-page":"23440","DOI":"10.1021\/acs.analchem.5c07732","article-title":"Overcoming electrochemiluminescence immunoassay (ECLIA) limitations: conformation-independent quantitation of a therapeutic antibody by LC\u2013MS\/MS","volume":"98","author":"Filion","year":"2026","journal-title":"Anal. Chem."},{"key":"10.1016\/j.jpba.2026.117752_bib13","doi-asserted-by":"crossref","first-page":"20","DOI":"10.3390\/labmed3030020","article-title":"Development of an LC-MS\/MS method for simultaneous quantification of ibrutinib and ritonavir in plasma and dried plasma spots","volume":"3","author":"Jager","year":"2026","journal-title":"LabMed"},{"key":"10.1016\/j.jpba.2026.117752_bib14","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1021\/acs.analchem.1c04338","article-title":"Multiplexed quantitative analysis of antibody-drug conjugates with labile CBI-Dimer payloads in vivo using immunoaffinity LC-MS\/MS","volume":"94","author":"Hyung","year":"2022","journal-title":"Anal. Chem."},{"key":"10.1016\/j.jpba.2026.117752_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2025.117117","article-title":"Antibody-free quantification of serum infliximab using LC-MS\/MS","volume":"266","author":"He","year":"2025","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2026.117752_bib16","doi-asserted-by":"crossref","first-page":"265","DOI":"10.4155\/bio-2020-0262","article-title":"Bioanalysis of therapeutic monoclonal antibody by peptide adsorption-controlled LC-MS","volume":"13","author":"Hashii","year":"2021","journal-title":"Bioanalysis"},{"key":"10.1016\/j.jpba.2026.117752_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2023.115730","article-title":"Determination of plasma concentration of belimumab by LC-MS\/MS: method development, validation, and clinical application","volume":"236","author":"Marin","year":"2023","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2026.117752_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2024.116627","article-title":"Quantification of serum daratumumab in multiple myeloma patients by LC-MS\/MS, comparison with ELISA","volume":"255","author":"Li","year":"2025","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2026.117752_bib19","doi-asserted-by":"crossref","first-page":"763","DOI":"10.4155\/bio.14.308","article-title":"Antibody-free workflows for protein quantification by LC-MS\/MS","volume":"7","author":"Wilffert","year":"2015","journal-title":"Bioanalysis"},{"key":"10.1016\/j.jpba.2026.117752_bib20","doi-asserted-by":"crossref","first-page":"979","DOI":"10.4155\/bio-2018-0056","article-title":"Enrichment of protein therapeutics and biomarkers for LC-MS quantification","volume":"10","author":"Pu","year":"2018","journal-title":"Bioanalysis"},{"key":"10.1016\/j.jpba.2026.117752_bib21","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1007\/s11095-024-03759-2","article-title":"Generic enrichment method for liquid chromatography-multiple reaction monitoring-mass spectrometry assay for quantitative measurement of biological therapeutics in serum","volume":"41","author":"Zhang","year":"2024","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jpba.2026.117752_bib22","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1021\/ac504502e","article-title":"Inline protein A mass spectrometry for characterization of monoclonal antibodies","volume":"87","author":"Prentice","year":"2015","journal-title":"Anal. Chem."},{"key":"10.1016\/j.jpba.2026.117752_bib23","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1466372","article-title":"Immunogenicity of dupilumab in adult and pediatric patients with atopic dermatitis","volume":"15","author":"Kamal","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jpba.2026.117752_bib24","unstructured":"ICH. (2022). ICH guideline M10 on bioanalytical method validation and study sample analysis. https:\/\/database.ich.org\/sites\/default\/files\/M10_Guideline_Step4_2022_0524.pdf."},{"key":"10.1016\/j.jpba.2026.117752_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.talanta.2023.124349","article-title":"Aptamer-based sample purification for mass spectrometric quantification of trastuzumab in human serum","volume":"257","author":"Sun","year":"2023","journal-title":"Talanta"},{"key":"10.1016\/j.jpba.2026.117752_bib26","doi-asserted-by":"crossref","first-page":"19550","DOI":"10.1039\/D4RA03060E","article-title":"Simultaneous quantification of co-administered trastuzumab and pertuzumab in serum based on nano-surface and molecular-orientation limited (nSMOL) proteolysis","volume":"14","author":"Liu","year":"2024","journal-title":"RSC Adv."},{"key":"10.1016\/j.jpba.2026.117752_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.chroma.2021.462489","article-title":"A generic sample preparation method for the multiplex analysis of seven therapeutic monoclonal antibodies in human plasma or serum with liquid chromatography-tandem mass spectrometry","volume":"1655","author":"Amrani","year":"2021","journal-title":"J. Chromatogr. A"}],"container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708526004206?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708526004206?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T21:25:39Z","timestamp":1793309139000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0731708526004206"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2027,1]]},"references-count":27,"alternative-id":["S0731708526004206"],"URL":"https:\/\/doi.org\/10.1016\/j.jpba.2026.117752","relation":{},"ISSN":["0731-7085"],"issn-type":[{"value":"0731-7085","type":"print"}],"subject":[],"published":{"date-parts":[[2027,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"LC-MS\/MS method for quantification of dupilumab in human serum using Protein G enrichment","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical and Biomedical Analysis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpba.2026.117752","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"117752"}}